Cargando…

Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique

BACKGROUND: Up to half of the heritable mutations in breast cancer (BC) are attributed to BRCA1 and BRCA2 genes. The mutation prevalence is variable based on ethnicity and may be influenced by founder mutations. The aim of this pilot study is to determine for the first time, the prevalence of BRCA1...

Descripción completa

Detalles Bibliográficos
Autores principales: Mogahed, Salwa H Gomaa, Hamed, Yasser S, Moursy, Yassmin E Ibrahim, Saied, Marwa H Mahomoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332123/
https://www.ncbi.nlm.nih.gov/pubmed/32102521
http://dx.doi.org/10.31557/APJCP.2020.21.2.431
_version_ 1783553466737623040
author Mogahed, Salwa H Gomaa
Hamed, Yasser S
Moursy, Yassmin E Ibrahim
Saied, Marwa H Mahomoud
author_facet Mogahed, Salwa H Gomaa
Hamed, Yasser S
Moursy, Yassmin E Ibrahim
Saied, Marwa H Mahomoud
author_sort Mogahed, Salwa H Gomaa
collection PubMed
description BACKGROUND: Up to half of the heritable mutations in breast cancer (BC) are attributed to BRCA1 and BRCA2 genes. The mutation prevalence is variable based on ethnicity and may be influenced by founder mutations. The aim of this pilot study is to determine for the first time, the prevalence of BRCA1 5382insC founder mutation in a cohort of Egyptian familial breast cancer patients (FBC). METHODS: Female patients were selected to have familial type of breast cancer. Twenty healthy females were included as a control group. Peripheral blood samples were withdrawn from all studied females and were analyzed for BRCA1 5382insC founder mutation detection using pyrosequencing technique. RESULTS: Eighty Egyptian FBC females were eligible to be enrolled in the study with a mean age of 48.31 ± 10.97years.We found a BRCA1 5382insC mutation carrier frequency of 5% of total studied FBC patients (4 out of 80 patients) with 95% confidence interval (1.61-12.99). There was a high statistical significant difference between carriers and non-carriers concerning the number of affected family members by BC, (p=0.001). CONCLUSION: BRCA1 5382insC founder mutation is not uncommon among Egyptian FBC females. The carrier frequency is comparable to that reported worldwide; however it is lower than those from previous Egyptian studies using different molecular techniques. The strong association between the mutation and the number of affected family members suggest wider screening of the mutation among high risk families using the reliable pyrosequencing technique.
format Online
Article
Text
id pubmed-7332123
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-73321232020-07-07 Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique Mogahed, Salwa H Gomaa Hamed, Yasser S Moursy, Yassmin E Ibrahim Saied, Marwa H Mahomoud Asian Pac J Cancer Prev Research Article BACKGROUND: Up to half of the heritable mutations in breast cancer (BC) are attributed to BRCA1 and BRCA2 genes. The mutation prevalence is variable based on ethnicity and may be influenced by founder mutations. The aim of this pilot study is to determine for the first time, the prevalence of BRCA1 5382insC founder mutation in a cohort of Egyptian familial breast cancer patients (FBC). METHODS: Female patients were selected to have familial type of breast cancer. Twenty healthy females were included as a control group. Peripheral blood samples were withdrawn from all studied females and were analyzed for BRCA1 5382insC founder mutation detection using pyrosequencing technique. RESULTS: Eighty Egyptian FBC females were eligible to be enrolled in the study with a mean age of 48.31 ± 10.97years.We found a BRCA1 5382insC mutation carrier frequency of 5% of total studied FBC patients (4 out of 80 patients) with 95% confidence interval (1.61-12.99). There was a high statistical significant difference between carriers and non-carriers concerning the number of affected family members by BC, (p=0.001). CONCLUSION: BRCA1 5382insC founder mutation is not uncommon among Egyptian FBC females. The carrier frequency is comparable to that reported worldwide; however it is lower than those from previous Egyptian studies using different molecular techniques. The strong association between the mutation and the number of affected family members suggest wider screening of the mutation among high risk families using the reliable pyrosequencing technique. West Asia Organization for Cancer Prevention 2020 /pmc/articles/PMC7332123/ /pubmed/32102521 http://dx.doi.org/10.31557/APJCP.2020.21.2.431 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mogahed, Salwa H Gomaa
Hamed, Yasser S
Moursy, Yassmin E Ibrahim
Saied, Marwa H Mahomoud
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title_full Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title_fullStr Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title_full_unstemmed Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title_short Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
title_sort analysis of heterozygous brca1 5382ins founder mutation in a cohort of egyptian breast cancer female patients using pyrosequencing technique
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332123/
https://www.ncbi.nlm.nih.gov/pubmed/32102521
http://dx.doi.org/10.31557/APJCP.2020.21.2.431
work_keys_str_mv AT mogahedsalwahgomaa analysisofheterozygousbrca15382insfoundermutationinacohortofegyptianbreastcancerfemalepatientsusingpyrosequencingtechnique
AT hamedyassers analysisofheterozygousbrca15382insfoundermutationinacohortofegyptianbreastcancerfemalepatientsusingpyrosequencingtechnique
AT moursyyassmineibrahim analysisofheterozygousbrca15382insfoundermutationinacohortofegyptianbreastcancerfemalepatientsusingpyrosequencingtechnique
AT saiedmarwahmahomoud analysisofheterozygousbrca15382insfoundermutationinacohortofegyptianbreastcancerfemalepatientsusingpyrosequencingtechnique